Nature Communications (Sep 2017)
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
- Kirstine Jacobsen,
- Jordi Bertran-Alamillo,
- Miguel Angel Molina,
- Cristina Teixidó,
- Niki Karachaliou,
- Martin Haar Pedersen,
- Josep Castellví,
- Mónica Garzón,
- Carles Codony-Servat,
- Jordi Codony-Servat,
- Ana Giménez-Capitán,
- Ana Drozdowskyj,
- Santiago Viteri,
- Martin R. Larsen,
- Ulrik Lassen,
- Enriqueta Felip,
- Trever G. Bivona,
- Henrik J. Ditzel,
- Rafael Rosell
Affiliations
- Kirstine Jacobsen
- Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark
- Jordi Bertran-Alamillo
- Laboratory of Oncology, Pangaea Biotech, Quiron Dexeus University Hospital
- Miguel Angel Molina
- Laboratory of Oncology, Pangaea Biotech, Quiron Dexeus University Hospital
- Cristina Teixidó
- Laboratory of Oncology, Pangaea Biotech, Quiron Dexeus University Hospital
- Niki Karachaliou
- Instituto Oncológico Dr. Rosell, University Hospital Sagrat Cor
- Martin Haar Pedersen
- Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark
- Josep Castellví
- Laboratory of Oncology, Pangaea Biotech, Quiron Dexeus University Hospital
- Mónica Garzón
- Laboratory of Oncology, Pangaea Biotech, Quiron Dexeus University Hospital
- Carles Codony-Servat
- Laboratory of Oncology, Pangaea Biotech, Quiron Dexeus University Hospital
- Jordi Codony-Servat
- Laboratory of Oncology, Pangaea Biotech, Quiron Dexeus University Hospital
- Ana Giménez-Capitán
- Laboratory of Oncology, Pangaea Biotech, Quiron Dexeus University Hospital
- Ana Drozdowskyj
- Pivotal
- Santiago Viteri
- Instituto Oncológico Dr. Rosell, Quiron-Dexeus University Hospital
- Martin R. Larsen
- Protein Research Group, Institute of Biochemistry and Molecular Biology, University of Southern Denmark
- Ulrik Lassen
- Phase I Unit, Rigshospitalet
- Enriqueta Felip
- Department of Medical Oncology, Vall D´Hebron
- Trever G. Bivona
- Department of Medicine, Division of Hematology and Oncology, University of California
- Henrik J. Ditzel
- Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark
- Rafael Rosell
- Laboratory of Oncology, Pangaea Biotech, Quiron Dexeus University Hospital
- DOI
- https://doi.org/10.1038/s41467-017-00450-6
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 14
Abstract
EGFR-mutant non-small cell lung cancer are often resistant to EGFR tyrosine kinase inhibitor treatment. In this study, the authors show that resistant tumors display high Akt activation and that a combined treatment with AKT inhibitors causes synergistic tumour growth inhibition in vitro and in vivo.
